Objectives
==========

\(1\) Did early magnetic resonance imaging (MRI) correctly identify \'responders\'? (2) Did MRI at the end of treatment correctly identify residual disease?

Method
======

Patients were assessed with mammography, ultrasound and MRI prior to treatment and had a second MRI scan after two pulses of chemotherapy. Mammography, ultrasound and MRI were then repeated at the end of treatment. Response at MRI was determined by a combination of size, morphological appearance and enhancement profile.

Results
=======

Eleven patients were studied. Four patients presented with primary breast tumour and clinically enlarged axillary lymph nodes. Seven patients presented with large tumours (\>30 mm). Patients were divided into responders/non-responders based on a greater than 50% reduction in size at mammography and ultrasound at completion of treatment. In the first group, there were three responders and one non-responder. In the second group, there were four responders and three non-responders. All responders were identified at the early MRI scan. All patients had residual disease at surgery. MRI was a useful adjunct to mammography and ultrasound but still tended to underestimate the extent of residual disease.

Conclusion
==========

\(1\) MRI provides additional information about the extent of disease before and after chemotherapy treatment. (2) Early MRI (after two pulses) predicted response to chemotherapy.
